Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Common Equity (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Common Equity for 15 consecutive years, with $3.3 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 25.62% year-over-year to $3.3 billion, compared with a TTM value of $3.3 billion through Dec 2025, up 25.62%, and an annual FY2025 reading of $3.3 billion, up 25.62% over the prior year.
  • Common Equity was $3.3 billion for Q4 2025 at Neurocrine Biosciences, up from $3.0 billion in the prior quarter.
  • Across five years, Common Equity topped out at $3.3 billion in Q4 2025 and bottomed at $1.2 billion in Q1 2021.
  • Average Common Equity over 4 years is $2.2 billion, with a median of $2.4 billion recorded in 2024.
  • The sharpest move saw Common Equity skyrocketed 72.15% in 2021, then increased 6.27% in 2025.
  • Year by year, Common Equity stood at $1.3 billion in 2021, then surged by 65.82% to $2.2 billion in 2023, then grew by 16.03% to $2.6 billion in 2024, then rose by 25.62% to $3.3 billion in 2025.
  • Business Quant data shows Common Equity for NBIX at $3.3 billion in Q4 2025, $3.0 billion in Q3 2025, and $2.7 billion in Q2 2025.